CClinicalTrials.gg
RecruitingNCT05734274Updated Nov 28, 2023

Clinical Effects of Limosilactobacillus Reuteri Probiotics as an Adjunct to the Treatment of Periodontitis

An interventional study of Probiotics and Negative control in Chronic Periodontitis, Generalized, sponsored by Universidade do Porto. Recruiting at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-28.

Sponsored by Universidade do Porto · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the clinical efficacy of a probiotic lozenge containing Limosilactobacillus reuteri as an adjunct to the periodontal non-surgical treatment of patients with stage II, grade A, B and C, generalized periodontitis.

Read the detailed description

The main purpose of this study is to assess the effect on disease progression of the probiotic Limosilactobacillus reuteri as an adjunct in the non-surgical periodontal treatment in patients with stage II, grade A, B and C, generalized periodontitis: evaluated by Bleeding on Probing (BoP) - Lindhe, 1972. The secondary purpose is to evaluate the effect of this probiotic on the values of Plaque Index (PI) - Silness \& Löe, 1964; Gingival Index (GI) - Löe \& Silness, 1963; Probing Pocket Depth (PPD), Clinical Attachment Level (CAL) - Ramfjord, 1959, when compared to a negative control product.

02

Conditions studied

  • Chronic Periodontitis, Generalized

Keywords

  • probiotics
  • Limosilactobacillus reuteri
03

In context

Periodontitis

1,635 studies on the registry are indexed under Periodontitis; 327 are open to participants now.

This study's planned enrollment of 60 is above the median of 45 across 1,191 interventional studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

Universidade do Porto is the lead sponsor of 170 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients over 18 years old, who intend to voluntarily participate in the study and:

    • Have a definitive diagnosis of stage II, grade A, B or C, generalized periodontitis (2018, World Workshop);
    • Have at least 3 natural teeth maintained per quadrant.

Exclusion criteria

Exclusion Criteria:

    • Patients unable to understand the instructions necessary to participate in the study or unable to give informed consent;

      • Patients who have received any type of periodontal treatment 2 months prior to the start of study participation;
      • Pregnant or breastfeeding patients;
      • Patients with associated systemic pathology, such as diabetes, HIV, asthma, hyperthyroidism, immune system pathologies, lichen erosive or other pathologies treated with corticosteroids or immunosuppressants;
      • Patients undergoing therapy with drugs that may interfere with the response of the gingival tissues: anti-inflammatory drugs, anticonvulsants (phenytoin and sodium valproate), immunosuppressants (cyclosporin-A and tacrolimus) and antihypertensives (nifedipine and verapamil hydrochloride);
      • Patients undergoing anticoagulant therapy;
      • Patients allergic to both lidocaine, articaine and mepivacaine;
      • Patients who require antibiotic prophylaxis for bacterial endocarditis;
      • Patients who have had antibiotic therapy within 2 months of study participation;
      • Patients using chlorhexidine, or other mouthwashes or elixirs;
      • Patients undergoing orthodontic treatment.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Probiotics Lozenge

    Subjects are instructed to take a lozenge twice a day, after brushing, in the morning and the evening.

    Other: Probiotics

  • Sham comparator
    Negative control Lozenge

    Subjects are instructed to take a lozenge twice a day, after brushing, in the morning and the evening.

    Other: Negative control

Interventions

  • OtherProbiotics

    Probiotics lozenge containing at least 200 million active Limosilactobacillus reuteri.

  • OtherNegative control

    Sugar-free negative control lozenges.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Bleeding on Probing (BoP) - Lindhe, 1972

    Bleeding on probing (in percentage) will be assessed 30 seconds after probing, through a dichotomous scoring system used at six sites per tooth using one (1) and zero (0) for presence or absence, respectively.

    Time frame: 0, 21, 90, 180 days

Secondary outcomes

  1. Change From Baseline in Plaque Index (PI) - Silness & Löe, 1964

    Each of the four gingival areas of the tooth (mesialbuccal, buccal, distobuccal and palatinal/lingual) is given a score from 0-3; this is the Pl for the area (using plaque discloser. The scores from the four areas of the tooth may be added and divided by four to give the Pl for the tooth. Finally, by adding the indices for the teeth and dividing by the number of teeth examined, the Pl for the individual is obtained. Scores criteria: 0 Absence of microbial plaque. 1. Thin film of microbial plaque along the free gingival margin. 2. Moderate accumulation with plaque in the sulcus. 3. Large amount of plaque in sulcus or pocket along the free gingiva margin.

    Time frame: 0, 21, 90, 180 days

  2. Change From Baseline in Gingival Index (GI) - Löe e Silness, 1963

    Four gingival areas of the tooth (mesialbuccal, buccal, distobuccal and palatinal/lingual) are given a score from 0 to 3; this is the Gl for the area. The scores from the four areas of the tooth may be added and divided by four to give the GI for the tooth. Finally, by adding the indices for the teeth and dividing by the total number of teeth examined, the Gl for the individual is obtained. The index for the subject is thus an average score for the areas examined. Scores criteria: 0 Normal gingiva: Natural coral pink gingival with no e/o inflammation. 1. Mild inflammation: Slight changes in color, slight edema. No bleeding on probing. 2. Moderate inflammation: Redness, edema and glazing. Bleeding upon probing. 3. Severe inflammation: Marked redness and edema/ulceration/tendency to bleed spontaneously.

    Time frame: 0, 21, 90, 180 days

  3. Change From Baseline in Probing Depth (PD)

    The distance measured from the base of the sulcus or pocket to the free gingival margin.

    Time frame: 0, 21, 90, 180 days

  4. Change From Baseline in Clinical Attachment Level (CAL) - Ramfjord, 1959

    It is calculated by adding the Probing Pocket Depth to the distance between the cementoenamel junction and the gingival margin (if it is a recession, the value is positive, if it is an increase in gingival volume the recorded value is negative).

    Time frame: 0, 21, 90, 180 days

07

Study locations

1 of 1 sites recruiting
  • Faculty of Dental Medicine - University of Porto
    Oporto, 4200-393, Portugal
    Recruiting
08

References and documents

Publications

  • Wei SH, Lang NP. Periodontal epidemiological indices for children and adolescents: II. Evaluation of oral hygiene; III. Clinical applications. Pediatr Dent. 1982 Mar;4(1):64-73. No abstract available. PubMed 6960328 ↗
  • Montero E, Iniesta M, Rodrigo M, Marin MJ, Figuero E, Herrera D, Sanz M. Clinical and microbiological effects of the adjunctive use of probiotics in the treatment of gingivitis: A randomized controlled clinical trial. J Clin Periodontol. 2017 Jul;44(7):708-716. doi: 10.1111/jcpe.12752. Epub 2017 Jun 23. PubMed 28556062 ↗
  • Iniesta M, Herrera D, Montero E, Zurbriggen M, Matos AR, Marin MJ, Sanchez-Beltran MC, Llama-Palacio A, Sanz M. Probiotic effects of orally administered Lactobacillus reuteri-containing tablets on the subgingival and salivary microbiota in patients with gingivitis. A randomized clinical trial. J Clin Periodontol. 2012 Aug;39(8):736-44. doi: 10.1111/j.1600-051X.2012.01914.x. Epub 2012 Jun 13. PubMed 22694350 ↗
  • Vivekananda MR, Vandana KL, Bhat KG. Effect of the probiotic Lactobacilli reuteri (Prodentis) in the management of periodontal disease: a preliminary randomized clinical trial. J Oral Microbiol. 2010 Nov 2;2. doi: 10.3402/jom.v2i0.5344. PubMed 21523225 ↗
  • Song D, Liu XR. Role of probiotics containing Lactobacillus reuteri in adjunct to scaling and root planing for management of patients with chronic periodontitis: a meta-analysis. Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4495-4505. doi: 10.26355/eurrev_202004_21032. PubMed 32373987 ↗
  • Tekce M, Ince G, Gursoy H, Dirikan Ipci S, Cakar G, Kadir T, Yilmaz S. Clinical and microbiological effects of probiotic lozenges in the treatment of chronic periodontitis: a 1-year follow-up study. J Clin Periodontol. 2015 Apr;42(4):363-72. doi: 10.1111/jcpe.12387. Epub 2015 Apr 10. PubMed 25728888 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05734274
Lead sponsor
Universidade do Porto
Responsible party
André Marques (Principal investigator - student of the Specialization in Periodontology and Oral Implants, Universidade do Porto) — Principal investigator
First posted
Feb 17, 2023
Start date
Feb 1, 2023
Primary completion
Jan 2024 (estimated)
Completion
Jul 2024 (estimated)
Last update
Nov 28, 2023

Study contacts

André Marques, MDent
Contact
andrecnbmarques@hotmail.com
+351965074955
André Marques, MDent
principal investigator · Estudante da Especialização de Periodontologia e Implantologia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion